文献速递心脑血管急症消化、代谢与肾脏急症

替尔泊肽与度拉糖肽在2型糖尿病中的心血管结局比较

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
PubMed 文献 · N Engl J Med · 2025-01-01
一句话结论在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,替尔泊肽的心血管复合终点不劣于度拉糖肽(HR 0.92,95.3%CI 0.83–1.01)。

SURPASS-CVOT是一项活性对照、双盲、非劣效性试验,纳入2型糖尿病合并动脉粥样硬化性心血管疾病患者,1:1随机接受每周皮下注射替尔泊肽(最大15 mg)或度拉糖肽1.5 mg。改良意向治疗人群替尔泊肽组6586例、度拉糖肽组6579例。主要终点(心血管原因死亡、心肌梗死或卒中复合终点)替尔泊肽组801例(12.2%)vs 度拉糖肽组862例(13.1%),HR 0.92(95.3%CI 0.83–1.01),非劣效性P=0.003,优效性P=0.09。两组不良事件发生率似乎相似,替尔泊肽组胃肠道不良事件更多。

要点

  • 在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,替尔泊肽主要心血管复合终点不劣于度拉糖肽(HR 0.92,95.3%CI 0.83–1.01,非劣效性P=0.003)。
  • 替尔泊肽对度拉糖肽的优效性未达统计学显著(优效性P=0.09)。
  • 主要终点事件替尔泊肽组801例(12.2%)vs 度拉糖肽组862例(13.1%)。
  • 两组不良事件发生率似乎相似,替尔泊肽组胃肠道不良事件更多。
  • 改良意向治疗人群替尔泊肽组6586例、度拉糖肽组6579例;平均年龄64.1±8.8岁,平均体重指数32.6±5.5,平均糖化血红蛋白8.4±0.9%。

适用人群与场景

  • 2型糖尿病合并动脉粥样硬化性心血管疾病患者;改良意向治疗人群替尔泊肽组6586例、度拉糖肽组6579例。

处置流程与药物剂量

  • 替尔泊肽每周皮下注射一次,最大剂量15 mg;度拉糖肽1.5 mg每周皮下注射一次;两组均为双盲、1:1随机分配。

研究设计与关键结果

  • 研究类型:活性对照、双盲、非劣效性试验;改良意向治疗人群替尔泊肽组6586例、度拉糖肽组6579例;人群为2型糖尿病合并动脉粥样硬化性心血管疾病患者。
  • 主要终点(心血管原因死亡、心肌梗死或卒中复合终点)替尔泊肽组801例(12.2%)vs 度拉糖肽组862例(13.1%),HR 0.92(95.3%CI 0.83–1.01),非劣效性P=0.003,优效性P=0.09。
  • 两组不良事件发生率似乎相似,替尔泊肽组胃肠道不良事件更多。
  • 患者平均年龄64.1±8.8岁,女性占29.0%,平均体重指数32.6±5.5,平均糖化血红蛋白8.4±0.9%,平均糖尿病病程14.7±8.8年。

证据类型、等级与局限

  • 证据类型:活性对照、双盲、非劣效性随机对照试验。
  • 非劣效性界值:风险比95.3%置信区间上限为1.05;上限小于1.00认为替尔泊肽优效。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于2型糖尿病合并动脉粥样硬化性心血管疾病患者,替尔泊肽在心血管复合终点上不劣于度拉糖肽,替尔泊肽组胃肠道不良事件更多。
  • 作者认为,在该人群中替尔泊肽对心血管原因死亡、心肌梗死或卒中复合终点不劣于度拉糖肽。

指南或共识出处

  • SURPASS-CVOT试验,ClinicalTrials.gov注册号NCT04255433,由Eli Lilly资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain.

METHODS: We conducted an active-comparator-controlled, double-blind, noninferiority trial in which patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomly assigned in a 1:1 ratio to receive a weekly subcutaneous injection of tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), an agent that has been shown to reduce the incidence of cardiovascular events. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke and was tested for noninferiority of tirzepatide to dulaglutide with a margin of 1.05 for the upper limit of the 95.3% confidence interval for the hazard ratio. An upper limit of less than 1.00 was considered to indicate superiority of tirzepatide to dulaglutide.

RESULTS: A total of 13,299 patients underwent randomization; 134 were subsequently excluded because they did not meet inclusion criteria. The modified intention-to-treat population thus included 6586 patients in the tirzepatide group and 6579 in the dulaglutide group. The mean (±SD) age of the patients was 64.1±8.8 years, 29.0% were women, the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 32.6±5.5, the mean glycated hemoglobin level was 8.4±0.9%, and the mean duration of diabetes was 14.7±8.8 years. A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01; P = 0.003 for noninferiority; P = 0.09 for superiority). The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group.

CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction, or stroke. (Funded by Eli Lilly; SURPASS-CVOT ClinicalTrials.gov number, NCT04255433.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. PMID: 41406444. doi:10.1056/NEJMoa2505928

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。